Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection
Natalia Sherina, Antonio Piralla, Likun Du, et al.
Med (2021) Vol. 2, Iss. 3, pp. 281-295.e4
Open Access | Times Cited: 192

Showing 26-50 of 192 citing articles:

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
Chiara Agrati, Concetta Castilletti, Delia Goletti, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Olympic Games in COVID-19 times: lessons learned with special focus on the upcoming FIFA World Cup Qatar 2022
Ismail Dergaa, Helmi Ben Saad, Amine Souissi, et al.
British Journal of Sports Medicine (2022) Vol. 56, Iss. 12, pp. 654-656
Open Access | Times Cited: 34
Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID
Benjamin A. Krishna, Eleanor Y. Lim, Lenette Mactavous, et al.
EBioMedicine (2022) Vol. 81, pp. 104129-104129
Open Access | Times Cited: 34
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Sara Diani, Erika Leonardi, Attilio Cavezzi, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6272-6272
Open Access | Times Cited: 33
Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
Berik Khairullin, Kunsulu Zakaryа, Mukhit Orynbayev, et al.
EClinicalMedicine (2022) Vol. 50, pp. 101526-101526
Open Access | Times Cited: 30
T cell perturbations persist for at least 6 months following hospitalization for COVID-19
Melissa Govender, Francis R. Hopkins, Robin Göransson, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
Fabienne Venet, Morgane Gossez, Frank Bidar, et al.
EBioMedicine (2022) Vol. 78, pp. 103967-103967
Open Access | Times Cited: 29
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity
Stuart G. Tangye, Laurent Abel, Salah Al-Muhsen, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 4, pp. 818-831
Open Access | Times Cited: 29
Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
João Faro Viana, Marie‐Louise Bergman, Lígia Antunes Gonçalves, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID
Md Sahidul Islam, Zhaoxiong Wang, Mohamed Abdel‐Mohsen, et al.
Journal of Leukocyte Biology (2023) Vol. 113, Iss. 3, pp. 236-254
Open Access | Times Cited: 16
SARS-CoV-2–specific B- and T-cell immunity in a population-based study of young Swedish adults
Sophia Björkander, Likun Du, Fanglei Zuo, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 149, Iss. 1, pp. 65-75.e8
Open Access | Times Cited: 38
SARS-CoV-2–specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies
Anna Jeffery-Smith, Alice R. Burton, Sabela Lens, et al.
Journal of Clinical Investigation (2021) Vol. 132, Iss. 2
Open Access | Times Cited: 35
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study
Irene Cassaniti, Federica Bergami, Elena Percivalle, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 301.e1-301.e8
Open Access | Times Cited: 33
SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study
Willem A. Mak, Johannes G.M. Koeleman, Marijke van der Vliet, et al.
Journal of Infection (2021) Vol. 84, Iss. 2, pp. 171-178
Open Access | Times Cited: 33
A review on the immune responses against novel emerging coronavirus (SARS-CoV-2)
Ramin Lotfi, Rasoul Nasiri Kalmarzi, Seyed Askar Roghani
Immunologic Research (2021) Vol. 69, Iss. 3, pp. 213-224
Open Access | Times Cited: 32
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection
Margherita Rosati, Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 32
Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Patricia Kaaijk, Verónica Olivo Pimentel, Maarten E. Emmelot, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
Aleksei Titov, Regina Shaykhutdinova, Olga V. Shcherbakova, et al.
JCI Insight (2022) Vol. 7, Iss. 9
Open Access | Times Cited: 22
COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants
Holly A. Fryer, Gemma E. Hartley, Emily S.J. Edwards, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 7, pp. 1506-1518
Open Access | Times Cited: 13
kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers
José F. Varona, Rodrigo Madurga, Francisco Peñalver, et al.
European Journal of Internal Medicine (2021) Vol. 89, pp. 97-103
Open Access | Times Cited: 29
Longitudinal analysis of antibody decay in convalescent COVID-19 patients
Weiming Xia, Mingfei Li, Ying Wang, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 29
Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals
Nuria Tormo, David Navalpotro, María Martínez Martínez, et al.
Diagnostic Microbiology and Infectious Disease (2021) Vol. 102, Iss. 4, pp. 115573-115573
Open Access | Times Cited: 28
Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
Dorota Kamińska, Dominika Dęborska−Materkowska, Katarzyna Kościelska−Kasprzak, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1068-1068
Open Access | Times Cited: 21
Characterization of memory T cell subsets and common γ−chain cytokines in convalescent COVID-19 individuals
Anuradha Rajamanickam, Nathella Pavan Kumar, Arul Nancy Pandiaraj, et al.
Journal of Leukocyte Biology (2022) Vol. 112, Iss. 1, pp. 201-212
Open Access | Times Cited: 20
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2
Olaf Nickel, Alexandra Rockstroh, Johannes Wolf, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0263861-e0263861
Open Access | Times Cited: 20

Scroll to top